FIELD: pharmaceutics.
SUBSTANCE: invention refers to pharmaceutics, namely to application of apigenin as a medicinal agent possessing neurotropic activity for psychosis treatment. What is presented is the use of apigenin as a drug having neurotropic activity for treating psychosis.
EFFECT: invention widens the range of products for treating psychosis.
8 cl, 1 dwg, 1 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| USE OF CYNAROSIDE HAVING NEUROTROPIC ACTIVITY | 2023 |
|
RU2832839C1 |
| USE OF COSMOSIIN HAVING NEUROTROPIC ACTIVITY | 2023 |
|
RU2833214C1 |
| USE OF SALICIN HAVING NEUROTROPIC ACTIVITY | 2023 |
|
RU2832938C1 |
| USE OF ISORHAMNETIN 3-O-β-D-GLUCOPYRANOSIDE, HAVING NEUROTROPIC ACTIVITY | 2024 |
|
RU2833215C1 |
| USE OF OREGANOL A WITH NEUROTROPIC ACTIVITY | 2022 |
|
RU2802871C1 |
| USE OF GAULTERIN AS ANTIDEPRESSANT | 2023 |
|
RU2825385C1 |
| USE OF PATULYTHRIN AS AN ANTIDEPRESSANT | 2022 |
|
RU2802977C1 |
| USE OF DIHYDROQUERCETIN AS A DIURETIC, SALURETIC AND CREATININURETIC AGENT | 2022 |
|
RU2802874C1 |
| USE OF PINOSTROBIN AS DIURETIC AND CREATINURETIC AGENT | 2023 |
|
RU2816948C1 |
| ANTIDEPRESSANT, ANXIOLYTIC, NEUROPROTECTIVE AND IMMUNOSTIMULATING AGENT | 2010 |
|
RU2429834C1 |
